PF 06821497 is a potential drug for the treatment of Creutzfeldt-Jakob disease (CJD). It is a protein that belongs to the group of ubiquitin ligases. It has been shown to have high resistance against CJD, and it is thought that PF 06821497 may be able to block the apoptosis pathway by inhibiting the activity of caspase-3 and caspase-6. This drug has been shown to inhibit neurogranin degradation in experimental models and it has been tested in clinical trials for CJD patients.